Document is current
Any future updates will be listed below
-
Authors
Goswami, Meghali
Gui, Gege
Dillon, Laura W
Lindblad, Katherine E
Thompson, Julie
Valdez, Janet
Kim, Dong-Yun
Ghannam, Jack Y https://orcid.org/0000-0003-0275-9099
Oetjen, Karolyn A
Destefano, Christin B
Smith, Dana M
Tekleab, Hanna
Li, Yeusheng
Dagur, Pradeep
Hughes, Thomas
Marté, Jennifer L
del Rivero, Jaydira
Klubo-Gwiezdzinksa, Joanna
Gulley, James L https://orcid.org/0000-0002-6569-2912
Calvo, Katherine R
Lai, Catherine
Hourigan, Christopher S https://orcid.org/0000-0002-6189-8067
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02996474 at ClinicalTrials.govnct02996474 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
https://doi.org/10.1136/jitc-2021-003392
nct02996474 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
https://doi.org/10.1136/jitc-2021-003392
nct02996474 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
https://doi.org/10.1136/jitc-2021-003392
nct04214249 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
https://doi.org/10.1136/jitc-2021-003392
nct04284787 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
https://doi.org/10.1136/jitc-2021-003392
nct02985554 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
https://doi.org/10.1136/jitc-2021-003392
nct03600155 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
https://doi.org/10.1136/jitc-2021-003392
nct02996474 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
https://doi.org/10.1136/jitc-2021-003392
Documents that mention this clinical trial
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
https://doi.org/10.1136/jitc-2021-003392
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute
Merck Sharpe & Dohme
Trans-NIH Center for Human Immunology.
- License Information
